Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. The combination of cisplatin (CDDP) plus cetuximab (CX) is one of the standard first-line treatments in this disease. However, this therapeutic regimen is often associated with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannelli, Federica, Zotti, Andrea Ilaria, Roca, Maria Serena, Grumetti, Laura, Lombardi, Rita, Moccia, Tania, Vitagliano, Carlo, Milone, Maria Rita, Ciardiello, Chiara, Bruzzese, Francesca, Leone, Alessandra, Cavalcanti, Ernesta, De Cecio, Rossella, Iachetta, Giuseppina, Valiante, Salvatore, Ionna, Franco, Caponigro, Francesco, Di Gennaro, Elena, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461984/
https://www.ncbi.nlm.nih.gov/pubmed/33015030
http://dx.doi.org/10.3389/fcell.2020.00732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461984/
https://www.ncbi.nlm.nih.gov/pubmed/33015030
http://dx.doi.org/10.3389/fcell.2020.00732

Ejemplares similares